team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.
Among people with secondary progressive multiple sclerosis (SPMS) without active disease, high blood levels of the proteins neurofilament light chain, known as NfL, and glial fibrillary acidic protein, or GFAP, are associated with an increased risk of worsening disability, new research shows.
Measuring levels of certain proteins in the blood can provide important information about a person’s health. NfL is released into the blood when neurons or nerve cells are damaged or destroyed. As such, levels of NfL in the blood are indicative of injury in the nervous system. GFAP, meanwhile, is associated with the activity of star-shaped neural support cells called astrocytes, and also is a marker of nervous system injury.
Evobrutinib is the First and Only BTK Inhibitor to Demonstrate Reduction of a Key Biomarker of Neuronal Damage and Inflammation in Patients with MS
businesswireindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesswireindia.com Daily Mail and Mail on Sunday newspapers.
Merck: Evobrutinib is the First and Only BTK Inhibitor to Demonstrate Reduction of a Key Biomarker of Neuronal Damage and Inflammation in Patients with MS
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Redirecting to Evobrutinib is the First and Only BTK Inhibitor to Demonstrate Reduction of a Key Biomarker of Neuronal Damage and Inflammation in Patients with MS
q8dailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from q8dailynews.com Daily Mail and Mail on Sunday newspapers.